BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

About this update from Biocardia, Inc.

[{"type":"image","alt":"BioCardia, Inc.","displaySize":"","headline":null,"caption":"BioCardia, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":68,"url":"https://media.zenfs.com/en/globenewswire.com/a5e6da8ba4e1db953fe3f1e134f34300"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9LRmPDXaunp8hOvXtHE3kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1/https://media.zenfs.com/en/globenewswire.com/a5e6da8ba4e1db953fe3f1e134f34300","width":300,"height":68},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/9LRmPDXaunp8hOvXtHE3kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1/https://media.zenfs.com/en/globenewswire.com/a5e6da8ba4e1db953fe3f1e134f34300","width":300,"height":68}},"lazy":false},{"type":"text","content":"SUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase.","length":297,"tagName":"p"},{"type":"text","content":"Fireside Chat Details:","length":22,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Time: 11:40 AM ET","length":17,"tagName":"p"}]},{"val":[{"type":"text","content":"Date: Wednesday, May 20, 2026","length":29,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":46,"olType":false},{"type":"text","content":"Investors can register for the conference and view the fireside chat here.","length":79,"tagName":"p"},{"type":"text","content":"About BioCardia®","length":16,"tagName":"p"},{"type":"text","content":"BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit: www.BioCardia.com.","length":482,"tagName":"p"},{"type":"text","content":"CONTACT: Media Contact: Miranda Peto, Investor Relations Email: [email protected] Phone: 650-226-0120 Investor Contact: David McClung, Chief Financial Officer Email: [email protected] Phone: 650-22...

More updates from Biocardia, Inc.